Table A1
Weights used in the case-mix standardization of survival estimates for all childhood cancers combined
Diagnostic group | Sex | |
---|---|---|
Male | Female | |
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases | 0.18618 | 0.16142 |
II. Lymphomas and reticuloendothelial neoplasms | 0.08484 | 0.04719 |
III. Central nervous system and miscellaneous intracranial and intraspinal neoplasms | 0.09541 | 0.08845 |
IV. Neuroblastoma and other peripheral nervous cell tumours | 0.03507 | 0.03326 |
V. Retinoblastoma | 0.01109 | 0.00670 |
VI. Renal tumours | 0.02192 | 0.02527 |
VII. Hepatic tumours | 0.00877 | 0.00413 |
VIII. Malignant bone tumours | 0.01831 | 0.02166 |
IX. Soft tissue and other extraosseous sarcomas | 0.03610 | 0.02991 |
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads | 0.01444 | 0.01831 |
XI. Other malignant epithelial neoplasms and malignant melanomas | 0.01444 | 0.02888 |
XII. Other and unspecified malignant neoplasms | 0.00387 | 0.00438 |
Note: Weights are based on the sex- and diagnostic-group-specific proportion of cases diagnosed in Canada (excluding Quebec) from 2010 to 2014. Source: Statistics Canada, Canadian Cancer Registry tabulation file (1992 to 2015), International Agency for Research on Cancer multiple primary rules version, released Janauary 29, 2018. |
Report a problem on this page
Is something not working? Is there information outdated? Can't find what you're looking for?
Please contact us and let us know how we can help you.
- Date modified: